You have not yet added any article to your bookmarks!
Join 10k+ people to get notified about new posts, news and tips.
Do not worry we don't spam!
Post by : Badri Ariffin
Abu Dhabi Biobank, a collaboration initiative led by the Department of Health – Abu Dhabi and M42, has entered into a partnership with global biopharmaceutical leader AstraZeneca to propel advancements in precision medicine and clinical research.
This collaboration merges Abu Dhabi Biobank's innovative biobanking, genomic capabilities, and population health metrics with AstraZeneca’s extensive expertise in critical therapy fields such as cardiovascular, renal, metabolic, respiratory, immunology, and oncology. The primary aim is to convert scientific research into health solutions.
Both organisations will jointly pursue various strategic focuses such as clinical development, precision medicine, and generating real-world evidence. Their efforts will enhance biomarker discovery, pharmacogenomics, and better patient stratification, enabling healthcare professionals to gain deeper insights into diseases and tailor treatments accordingly.
Additionally, this partnership will delve into health economics, regulatory science, and emerging domains like digital health and artificial intelligence. These initiatives are designed to fortify data-driven healthcare infrastructures and expedite the transition of research findings into clinical applications.
Albarah ElKhani, COO of Integrated Health Solutions at M42, expressed that the alliance signifies a mutual objective to redefine the future of medicine. He pointed out that blending comprehensive population data from Abu Dhabi Biobank with AstraZeneca’s scientific knowledge could unlock new avenues in disease prevention, diagnosis, and treatment, particularly for Middle Eastern demographics.
Sameh ElFangary, Country President for Gulf and Pakistan at AstraZeneca, emphasized that precision medicine should embody the diversity of populations worldwide. He mentioned that this collaboration will aid in the earlier identification of at-risk patients, especially in the context of rare and difficult-to-diagnose illnesses, contributing to the development of more tailored care plans.
This partnership signifies a key development in Abu Dhabi's ambition to establish itself as a leading center for biomedical research and life sciences innovation. By leveraging extensive population data and local insights, the collaboration seeks to hasten the journey from research discovery to regulatory endorsement and real-world application.
APEC Members Emphasise Safe and Responsible Use of Artificial Intelligence
APEC members discuss responsible AI use, digital innovation and data governance as China and the US
Union of European Clubs Challenge UEFA and EFC Over EU Competition Rules
UEC files an EU competition complaint against UEFA and EFC, challenging club representation, governa
Mohammed Shami Retires From Test Cricket, Eyes White-Ball Career
Mohammed Shami retires from Test cricket after 13 years, with 229 wickets. He will continue playing
Singapore Warns Users About Privacy and Security Risks of AI Agents
Singapore warns users about AI agent security risks, data privacy, online scams and unauthorised acc
Chris Lynn Completes One-Month Ban After Positive Cocaine Test
Australian cricketer Chris Lynn completes a one-month ban after a positive cocaine test during the T
Djokovic Eyes Strong Season Finish as Health Improves Ahead of Paris Masters
Novak Djokovic reports improved health and performance as he targets a strong Paris Masters finish a